Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitors”

2,466 pharma patents match "inhibitors" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,466
Index total 30,257
Page 89 / 103

Quick answer

This filtered view shows 2,466 pharmaceutical patents matching "inhibitors" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,466 results for “inhibitors” · 30,257 patents in full index Clear search

  1. US 7388002

    Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases

    BioCryst Pharmaceuticals, Inc. · Granted Jun 17, 2008 · Expires Jun 12, 2028

    granted
  2. US 7381825

    Histone deacetylase inhibitors

    Takeda San Diego, Inc. · Granted Jun 3, 2008 · Expires May 29, 2028

    granted
  3. US 7378403

    Akt inhibitors, pharmaceutical compositions, and uses thereof

    The United States of America, as represented by the Department of Health and Human Services · Granted May 27, 2008 · Expires May 22, 2028

    granted
  4. US 7378422

    Inhibitors of serine proteases, particularly HCV NS3-NS4A protease

    Vertex Pharmaceuticals Incorporated · Granted May 27, 2008 · Expires May 22, 2028

    granted
  5. US 7378552

    Monoamine re-uptake inhibitors and methods relating thereto

    Neurocrine Biosciences, Inc. · Granted May 27, 2008 · Expires May 22, 2028

    granted
  6. US 7375228

    Histone deacetylase inhibitors

    Takeda San Diego, Inc. · Granted May 20, 2008 · Expires May 15, 2028

    granted
  7. US 7375079

    Previns as specific inhibitors and therapeutic agents for botulinum toxin B and tetanus neurotoxins

    The United States of America as represented by the Secretary of the Army · Granted May 20, 2008 · Expires May 15, 2028

    granted
  8. US 7371372

    Compositions comprising IMPDH inhibitors and uses thereof for treating HCV infection

    Vertex Pharmaceuticals Incorporated · Granted May 13, 2008 · Expires May 8, 2028

    granted
  9. US 7368452

    Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors

    Enanta Pharmaceuticals, Inc. · Granted May 6, 2008 · Expires May 1, 2028

    granted
  10. US 7365072

    Inhibitors of p38

    Vertex Pharmaceuticals Incorporated · Granted Apr 29, 2008 · Expires Apr 24, 2028

    granted
  11. US 7365092

    Inhibitors of serine proteases, particularly HCV NS3-NS4A protease

    Vertex Pharmaceuticals Incorporated · Granted Apr 29, 2008 · Expires Apr 24, 2028

    granted
  12. US 7361665

    Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases

    Vertex Pharmaceuticals Incorporated · Granted Apr 22, 2008 · Expires Apr 17, 2028

    granted
  13. US 7358273

    Inhibitors of caspases

    Vertex Pharmaceuticals Incorporated · Granted Apr 15, 2008 · Expires Apr 10, 2028

    granted
  14. US 7358259

    HCV inhibitors and methods of using them

    Rigel Pharmaceuticals, Inc. · Granted Apr 15, 2008 · Expires Apr 10, 2028

    granted
  15. US 7354928

    Small molecule inhibitors targeted at Bcl-2

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted
  16. US 7354919

    Isoxazole compositions useful as inhibitors of ERK

    Vertex Pharmaceuticals Incorporated · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted
  17. US 7354580

    Method of administering and using VEGF inhibitors for the treatment of human cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted
  18. US 7354939

    Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto

    Vertex Pharmaceuticals Incorporated · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted
  19. US 7354578

    Method of tumor regression with VEGF inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted
  20. US 7351702

    Caspase inhibitors and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Apr 1, 2008 · Expires Mar 27, 2028

    granted
  21. US 7348335

    Compositions useful as inhibitors of JAK and other protein kinases

    Vertex Pharmaceuticals Incorporated · Granted Mar 25, 2008 · Expires Mar 20, 2028

    granted
  22. US 7345054

    Heterocyclic inhibitors of ERK2 and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Mar 18, 2008 · Expires Mar 13, 2028

    granted
  23. US 7338961

    Sphingosine kinase inhibitors

    Apogee Biotechnology Corporation · Granted Mar 4, 2008 · Expires Feb 28, 2028

    granted
  24. US 7335662

    Substituted tricyclic compounds as protein kinase inhibitors

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Feb 26, 2008 · Expires Feb 21, 2028

    granted